2025-12-20 - Analysis Report
Okay, here's a breakdown of the provided information on UnitedHealth Group (UNH), combining the numbers and analysis as requested.

**1) Return Rate Comparison:**

*   **Company Overview:** UnitedHealth Group Inc. is a diversified health care company offering a wide range of products and services, such as health insurance and healthcare technology.
*   **UNH Cumulative Return:** -18.40%
*   **VOO (S&P 500) Cumulative Return:** 100.88%
*   **Divergence:** -116.5 (Relative Divergence: 8.5)

**Analysis:** UNH has significantly underperformed the S&P 500 (VOO) over the tracked period. The divergence of -116.5 is substantial. The relative divergence of 8.5 suggests that the current divergence is near the low end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha  | Beta  | Cap(B) |
|------------|---------|--------|--------|-------|--------|
| 2015-2017  | 58.0%   | 66.4%  | 30.0%  | 0.1   | 199.7  |
| 2016-2018  | 41.0%   | 70.4%  | 26.0%  | 0.1   | 225.7  |
| 2017-2019  | 36.0%   | 73.8%  | 14.0%  | 0.2   | 266.3  |
| 2018-2020  | -43.0%  | 81.2%  | -67.0% | 0.5   | 317.7  |
| 2019-2021  | 16.0%   | 81.2%  | -30.0% | 1.5   | 454.9  |
| 2020-2022  | -1.0%   | 81.2%  | 0.0%   | 1.5   | 480.3  |
| 2021-2023  | 24.0%   | 80.8%  | 23.0%  | 0.4   | 476.9  |
| 2022-2024  | -27.0%  | 78.8%  | -47.0% | 0.3   | 458.2  |
| 2023-2025  | -61.0%  | 79.8%  | -126.0% | 1.2   | 296.6  |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows significant volatility, with periods of strong growth followed by steep declines. Recent years have been particularly weak.
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant risk of loss over these periods.
*   **Alpha:** Alpha, which measures performance relative to a benchmark, is negative in many periods, especially recently, indicating underperformance.
*   **Beta:** Beta fluctuates, indicating varying levels of volatility relative to the market.  A Beta near 1 suggests UNH's price moves roughly in line with the market, while values significantly above 1 indicate higher volatility.  Note the Beta increasing to 1.5 during 2019-2022 and then decreasing rapidly to 0.3.
*   **Cap(B):** Market capitalization shows steady growth until recently.

**2) Recent Stock Price Fluctuations:**

*   **Current Price:** 327.42
*   **Previous Close:** 328.14
*   **Change:** -0.22
*   **5-day SMA:** 332.498
*   **20-day SMA:** 329.988
*   **60-day SMA:** 340.1082

**Analysis:** The stock price closed slightly lower than the previous day. The 5-day SMA is above the 20-day SMA, which is a short-term bullish signal, but both are below the 60-day SMA, indicating a longer-term bearish trend.

**3) Indicators:**

*   **MRI:** 0.7 (Medium Investment)
*   **RSI:** 52.25 (Neutral)
*   **PPO:** 0.1151 (Neutral)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (2 shares - Safe - MRI:0.80) Dividend_2.21 (Cash Ratio: 0% on 2025-12-08)
*   **Recent Divergence Change:** 2.3 (+) (Short-term increase)
*   **Expected Return:** -216.9%

**Analysis:**

*   The MRI suggests a medium level of investment risk.
*   The RSI is in a neutral zone, neither overbought nor oversold.
*   The PPO, being close to zero, indicates the recent price is around its moving average.
*   The Hybrid Signal suggests a moderate buy signal, but with a low cash reserve.
*   The recent increase in divergence suggests a short-term upward trend.
*   The extremely negative Expected Return is a major cause for concern.

**4) Recent News & Significant Events:**

*   **Key Themes:** The news highlights concerns about policy risk, changes in Optum Rx (a UNH subsidiary), analyst reassessments following a price drop, external reviews of UNH's practices, and potential for recovery.  The "floor is set for recovery" suggests a belief that the worst may be over.  UnitedHealth is working on ensuring improvements after external audits, meaning they are taking proactive measures to improve after issues in the organization.

**Analysis:** Recent news suggests both challenges and potential opportunities for UnitedHealth.  Concerns exist about policy and operational changes, but the company is also taking steps to address issues and analysts are considering a potential recovery.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (1.96 on a scale of 1-5)
*   **Target Price:** Average: 392.24, High: 440.00, Low: 280.00
*   **Recent Rating Changes:** No specific changes noted.

**Analysis:** Despite the recent struggles, analysts generally have a "Buy" rating on UNH, with a significant upside potential based on the average target price. However, the wide range in target prices indicates some uncertainty.

**5) Recent Earnings Analysis:**

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2025-10-28 | 2.59 | 113.16 B$    |
| 2025-08-11 | 3.76 | 111.62 B$    |
| 2025-05-07 | 6.9  | 109.58 B$    |
| 2024-11-04 | 6.56 | 100.82 B$    |
| 2025-10-28 | 6.56 | 100.82 B$    |

**Analysis:** While revenue has been generally increasing, the most recent EPS figure (2.59) is noticeably lower than the previous quarters, which may be contributing to investor concern.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $113.16B   | 18.24%        |
| 2025-06-30   | $111.62B   | 17.93%        |
| 2025-03-31   | $109.58B   | 21.70%        |
| 2024-12-31   | $100.81B   | 21.14%        |
| 2024-09-30   | $100.82B   | 22.84%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE    |
|--------------|------------|--------|
| 2025-09-30   | $95.79B    | 2.45%  |
| 2025-06-30   | $94.72B    | 3.60%  |
| 2025-03-31   | $95.04B    | 6.62%  |
| 2024-12-31   | $92.66B    | 5.98%  |
| 2024-09-30   | $94.53B    | 6.41%  |

**Analysis:**

*   Revenue has shown growth. However, profit margins have decreased in recent quarters.
*   Equity has remained relatively stable.
*   Return on Equity (ROE) has decreased significantly in the most recent quarter. This decline in ROE suggests the company is generating less profit from shareholder equity.

**7) Comprehensive Analysis:**

**Summary:**

UnitedHealth Group (UNH) has experienced a significant downturn, underperforming the S&P 500.  The company faces challenges including lower recent EPS, declining profit margins and ROE, and policy risk. Technical indicators present a mixed picture, with a short-term bullish signal conflicting with a longer-term bearish trend. Analyst opinions remain generally positive, but with a wide range of target prices.

**Overall Recommendation:**

The data presents a cautious outlook. While analysts and the hybrid signal suggest a buy opportunity, the negative expected return, lower recent EPS, declining profitability metrics, and the negative cumulative return compared to the S&P 500 suggest significant risks. A potential investor should carefully consider the challenges facing UNH, perform further due diligence, and monitor the company's progress in addressing these issues before making an investment decision.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.